CXCL12/CXCR4 Blockade by Oncolytic Virotherapy Inhibits Ovarian Cancer Growth by Decreasing Immunosuppression and Targeting Cancer-Initiating Cells
暂无分享,去创建一个
M. Seshadri | M. Opyrchal | K. Odunsi | H. Rokita | M. Gil | Marcin Komorowski | D. Kozbor | A. McGray | Margaret Gil | R. Mcgray | Anna-Maria Kellen
[1] C. Landen,et al. Ovarian cancer stem cells: are they real and why are they important? , 2014, Gynecologic oncology.
[2] C. Morrison,et al. Ovarian Cancer Spheroid Cells with Stem Cell-Like Properties Contribute to Tumor Generation, Metastasis and Chemotherapy Resistance through Hypoxia-Resistant Metabolism , 2014, PloS one.
[3] A. Dubrovska,et al. Emerging targets in cancer management: role of the CXCL12/CXCR4 axis , 2013, OncoTargets and therapy.
[4] R. Buckanovich,et al. Ovarian cancer stem cells: working towards the root of stemness. , 2013, Cancer letters.
[5] M. Seshadri,et al. Targeting CXCL12/CXCR4 signaling with oncolytic virotherapy disrupts tumor vasculature and inhibits breast cancer metastases , 2013, Proceedings of the National Academy of Sciences.
[6] S. Ngai,et al. Ovarian Cancer Stem Cells: A New Target for Cancer Therapy , 2013, BioMed research international.
[7] A. Szalay,et al. Oncolytic vaccinia virus GLV-1h68 strain shows enhanced replication in human breast cancer stem-like cells in comparison to breast cancer cells , 2012, Journal of Translational Medicine.
[8] V. Seshan,et al. A CXCL1 Paracrine Network Links Cancer Chemoresistance and Metastasis , 2012, Cell.
[9] A. Chang,et al. Cancer stem cell vaccination confers significant antitumor immunity. , 2012, Cancer research.
[10] G. Coukos,et al. Prognostic significance of tumor-infiltrating T cells in ovarian cancer: a meta-analysis. , 2012, Gynecologic oncology.
[11] S. Biswas,et al. Characterization of the nature of granulocytic myeloid‐derived suppressor cells in tumor‐bearing mice , 2012, Journal of leukocyte biology.
[12] J. Diallo,et al. The Oncolytic Poxvirus JX-594 Selectively Replicates in and Destroys Cancer Cells Driven by Genetic Pathways Commonly Activated in Cancers , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.
[13] K. Odunsi,et al. PGE(2)-induced CXCL12 production and CXCR4 expression controls the accumulation of human MDSCs in ovarian cancer environment. , 2011, Cancer research.
[14] R. K. Pandey,et al. Photodynamic therapy augments the efficacy of oncolytic vaccinia virus against primary and metastatic tumours in mice , 2011, British Journal of Cancer.
[15] G. Mor,et al. Prevalence of Epithelial Ovarian Cancer Stem Cells Correlates with Recurrence in Early-Stage Ovarian Cancer , 2011, Journal of oncology.
[16] G. Dranoff,et al. CXCL12/CXCR4 blockade induces multimodal antitumor effects that prolong survival in an immunocompetent mouse model of ovarian cancer. , 2011, Cancer research.
[17] L. Gaboury,et al. CXCR4 peptide antagonist inhibits primary breast tumor growth, metastasis and enhances the efficacy of anti‐VEGF treatment or docetaxel in a transgenic mouse model , 2011, International journal of cancer.
[18] D. Armstrong. Update on treatment options for newly diagnosed ovarian cancer. , 2010, Clinical advances in hematology & oncology : H&O.
[19] C. Rancourt,et al. The inhibition of Bid expression by Akt leads to resistance to TRAIL-induced apoptosis in ovarian cancer cells , 2010, Oncogene.
[20] Xiaodong Huang,et al. Stromal Cell-Derived Factor-1/CXCL12 Contributes to MMTV-Wnt1 Tumor Growth Involving Gr1+CD11b+ Cells , 2010, PloS one.
[21] S. Bapat,et al. Cancer stem cells and aneuploid populations within developing tumors are the major determinants of tumor dormancy. , 2009, Cancer research.
[22] Abdelkader Essafi,et al. Wt1 is required for cardiovascular progenitor cell formation through transcriptional control of Snail and E-cadherin , 2009, Nature Genetics.
[23] H. Rokita,et al. Targeting a Mimotope Vaccine to Activating Fcγ Receptors Empowers Dendritic Cells to Prime Specific CD8+ T Cell Responses in Tumor-Bearing Mice1 , 2009, The Journal of Immunology.
[24] Massimo Cristofanilli,et al. A CXCR4 antagonist CTCE-9908 inhibits primary tumor growth and metastasis of breast cancer. , 2009, The Journal of surgical research.
[25] S. Gerber,et al. Omental immune aggregates and tumor metastasis within the peritoneal cavity , 2009, Immunologic research.
[26] D. Wong,et al. Translating an Antagonist of Chemokine Receptor CXCR4: From Bench to Bedside , 2008, Clinical Cancer Research.
[27] J. Visvader,et al. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions , 2008, Nature Reviews Cancer.
[28] M. Serio,et al. The critical role of SDF-1/CXCR4 axis in cancer and cancer stem cells metastasis , 2008, Journal of endocrinological investigation.
[29] Curt Balch,et al. Identification and characterization of ovarian cancer-initiating cells from primary human tumors. , 2008, Cancer research.
[30] Wenjun Guo,et al. The Epithelial-Mesenchymal Transition Generates Cells with Properties of Stem Cells , 2008, Cell.
[31] H. Broxmeyer,et al. Vaccinia Virus Infection Modulates the Hematopoietic Cell Compartments in the Bone Marrow , 2008, Stem cells.
[32] J. Aguirre-Ghiso,et al. Models, mechanisms and clinical evidence for cancer dormancy , 2007, Nature Reviews Cancer.
[33] H. Atkins,et al. Targeted inflammation during oncolytic virus therapy severely compromises tumor blood flow. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.
[34] K. Liang,et al. CXCR4/CXCL12 axis promotes VEGF-mediated tumor angiogenesis through Akt signaling pathway. , 2007, Biochemical and biophysical research communications.
[35] K. Odunsi,et al. Vaccination with an NY-ESO-1 peptide of HLA class I/II specificities induces integrated humoral and T cell responses in ovarian cancer , 2007, Proceedings of the National Academy of Sciences.
[36] Xiaopei Huang,et al. Innate immunity against vaccinia virus is mediated by TLR2 and requires TLR-independent production of IFN-beta. , 2007, Blood.
[37] M. Nachtigal,et al. Primary culture of ovarian surface epithelial cells and ascites-derived ovarian cancer cells from patients , 2006, Nature Protocols.
[38] Peter Hohenstein,et al. The many facets of the Wilms' tumour gene, WT1. , 2006, Human molecular genetics.
[39] Christopher Chiu,et al. Infiltrating neutrophils mediate the initial angiogenic switch in a mouse model of multistage carcinogenesis , 2006, Proceedings of the National Academy of Sciences.
[40] Robert A. Weinberg,et al. Stromal Fibroblasts in Cancer: A Novel Tumor-Promoting Cell Type , 2006, Cell cycle.
[41] Matthew L. Anderson,et al. Comparison of ID8 MOSE and VEGF-modified ID8 cell lines in an immunocompetent animal model for human ovarian cancer. , 2006, Anticancer research.
[42] Kunle Odunsi,et al. Expression of Wilms tumor gene (WT1) in epithelial ovarian cancer. , 2006, Gynecologic Oncology.
[43] Carl Nathan,et al. Neutrophils and immunity: challenges and opportunities , 2006, Nature Reviews Immunology.
[44] T. Kipps,et al. CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment. , 2006, Blood.
[45] Gerd Ritter,et al. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[46] M. Ratajczak,et al. Trafficking of Normal Stem Cells and Metastasis of Cancer Stem Cells Involve Similar Mechanisms: Pivotal Role of the SDF‐1–CXCR4 Axis , 2005, Stem cells.
[47] T. Curiel,et al. Plasmacytoid dendritic cells induce CD8+ regulatory T cells in human ovarian carcinoma. , 2005, Cancer research.
[48] Dennis C. Sgroi,et al. Stromal Fibroblasts Present in Invasive Human Breast Carcinomas Promote Tumor Growth and Angiogenesis through Elevated SDF-1/CXCL12 Secretion , 2005, Cell.
[49] Christie M. Orschell,et al. Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist , 2005, The Journal of experimental medicine.
[50] S. Bapat,et al. Stem and progenitor-like cells contribute to the aggressive behavior of human epithelial ovarian cancer. , 2005, Cancer research.
[51] Lieve Moons,et al. CXCL12 and vascular endothelial growth factor synergistically induce neoangiogenesis in human ovarian cancers. , 2005, Cancer research.
[52] George Coukos,et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival , 2004, Nature Medicine.
[53] P. Carmeliet,et al. Dendritic Cell Subsets Differentially Regulate Angiogenesis in Human Ovarian Cancer , 2004, Cancer Research.
[54] Napoleone Ferrara,et al. Vascular endothelial growth factor: basic science and clinical progress. , 2004, Endocrine reviews.
[55] N. Ferrara. Vascular endothelial growth factor as a target for anticancer therapy. , 2004, The oncologist.
[56] D. Pardoll,et al. Persistent Toll-like receptor signals are required for reversal of regulatory T cell–mediated CD8 tolerance , 2004, Nature Immunology.
[57] J. Dipersio,et al. Rapid mobilization of CD34+ cells following administration of the CXCR4 antagonist AMD3100 to patients with multiple myeloma and non-Hodgkin's lymphoma. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[58] Gordon Stamp,et al. Multiple actions of the chemokine CXCL12 on epithelial tumor cells in human ovarian cancer. , 2002, Cancer research.
[59] T. Curiel,et al. Stromal-derived factor-1 in human tumors recruits and alters the function of plasmacytoid precursor dendritic cells , 2001, Nature Medicine.
[60] Y. Sugisaki,et al. Prognostic significance of vascular endothelial growth factor expression in human ovarian carcinoma , 2000, British Journal of Cancer.
[61] K. Pillarisetti,et al. Cutting edge: CXCR4-Lo: molecular cloning and functional expression of a novel human CXCR4 splice variant. , 1999, Journal of immunology.
[62] R. Steinman,et al. Rapid generation of broad T-cell immunity in humans after a single injection of mature dendritic cells. , 1999, The Journal of clinical investigation.
[63] H. Etlinger,et al. the Journal of Immunology , 2006 .
[64] Robert B Sim,et al. Extracellular enveloped vaccinia virus is resistant to complement because of incorporation of host complement control proteins into its envelope. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[65] B. Moss,et al. Compact, synthetic, vaccinia virus early/late promoter for protein expression. , 1997, BioTechniques.
[66] T. Akiyama,et al. WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia. , 1994, Blood.
[67] A. Schneider-Gädicke,et al. Different human cervical carcinoma cell lines show similar transcription patterns of human papillomavirus type 18 early genes. , 1986, The EMBO journal.
[68] F. Jensen,et al. INFECTION OF HUMAN AND SIMIAN TISSUE CULTURES WITH ROUS SARCOMA VIRUS. , 1964, Proceedings of the National Academy of Sciences of the United States of America.
[69] S. Kleffel,et al. Tumor dormancy and cancer stem cells: two sides of the same coin? , 2013, Advances in experimental medicine and biology.
[70] M. Banerjee,et al. Expression of aldehyde dehydrogenase and CD133 defines ovarian cancer stem cells , 2012, International journal of cancer.
[71] D. Kirn,et al. Targeted and armed oncolytic poxviruses: a novel multi-mechanistic therapeutic class for cancer , 2009, Nature Reviews Cancer.
[72] Fumitaka Kikkawa,et al. Involvement of SDF-1alpha/CXCR4 axis in the enhanced peritoneal metastasis of epithelial ovarian carcinoma. , 2008, International journal of cancer.
[73] R. Ortíz-López,et al. Oncolytic virotherapy. , 2008, Annals of hepatology.
[74] Fumitaka Kikkawa,et al. Involvement of SDF‐1α/CXCR4 axis in the enhanced peritoneal metastasis of epithelial ovarian carcinoma , 2008 .
[75] D. Kozbor,et al. Oral vaccination with modified vaccinia virus Ankara attached covalently to TMPEG-modified cationic liposomes overcomes pre-existing poxvirus immunity from recombinant vaccinia immunization. , 2007, The Journal of general virology.
[76] A. Jemal,et al. Cancer Statistics, 2007 , 2007, CA: a cancer journal for clinicians.
[77] W. Zou,et al. Stromal derived factor ( SDF-1 / CXCL 12 ) and human tumor pathogenesis , 2006 .